TORONTO, March 3, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of ...

The SolidDrive speakers were chosen for their unique ability to transform surfaces into sound-producing elements with ...

With over 1,250 studies on hydrogen therapy, there’s growing interest in its benefits. Results may vary and research is ongoing for long term benefits. It has solid 8 ppm of molecular hydrogen ...

This study reveals that Fe-doped boron nitride nanoparticles improve Anastrozole delivery, offering enhanced stability and targeted therapy for breast cancer.

This device uses specialized LED, or light-emitting diode, therapy to stimulate collagen production ... including an array of ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

In this interview, Dr. Christian Schafmeister discusses the structural advantages of Spiroligomer molecules, their ability to ...

Twenty-three new Ngā Ahurei a Te Apārangi Fellows have been elected to the Academy of the Royal Society Te Apārangi. Fellowship recognises researchers, scholars, and innovators throughout Aotearoa New ...

Revive Therapeutics (RVVTF) has entered into a non-binding letter of intent, dated February 28, 2025, to acquire the full rights to DiagnaMed ...